Which two diseases contraindicate the use of PN IV lipids?

The use of parenteral nutrition (PN) intravenous lipids is carefully considered based on a patient's health status and specific diseases. Hyperlipidemia and severe hepatic disease are contraindications for the use of PN IV lipids because these conditions can significantly affect lipid metabolism and overall lipid levels in the bloodstream.

In hyperlipidemia, there is an abnormally high concentration of fats or lipids in the blood, and administering additional lipids can exacerbate this condition, potentially leading to complications such as pancreatitis. This makes it crucial to avoid intravenous lipid administration in patients whose lipid levels are already elevated.

Severe hepatic disease also poses a risk when it comes to lipid emulsions. The liver is responsible for metabolizing lipids and synthesizing lipoproteins that transport these fats throughout the body. In a patient with severe hepatic impairment, the liver's ability to process and clear lipid particles is compromised, which can lead to further liver dysfunction and complications.

In the context of this question, selecting hyperlipidemia and severe hepatic disease as the two diseases that contraindicate the use of PN IV lipids highlights the importance of balancing nutrient delivery while avoiding adverse effects in patients with pre-existing metabolic derangements related to lipids.